The University of Chicago Header Logo

Connection

Vesselin Dimov to Humans

This is a "connection" page, showing publications Vesselin Dimov has written about Humans.
Connection Strength

0.097
  1. Social Media and Allergy. Curr Allergy Asthma Rep. 2018 11 14; 18(12):76.
    View in: PubMed
    Score: 0.019
  2. Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults. Expert Opin Drug Metab Toxicol. 2017 Dec; 13(12):1275-1280.
    View in: PubMed
    Score: 0.018
  3. Investigational drugs for the treatment of allergic rhinitis. Expert Opin Investig Drugs. 2014 Jun; 23(6):823-36.
    View in: PubMed
    Score: 0.014
  4. Pharmacokinetic evaluation of topical calcineurin inhibitors for treatment of allergic conjunctivitis. Expert Opin Drug Metab Toxicol. 2014 Apr; 10(4):543-9.
    View in: PubMed
    Score: 0.014
  5. Innovations in technology: social media and mobile technology in the care of adolescents with asthma. Curr Allergy Asthma Rep. 2012 Dec; 12(6):607-12.
    View in: PubMed
    Score: 0.013
  6. Immunomodulators in asthma therapy. Curr Allergy Asthma Rep. 2009 Nov; 9(6):475-83.
    View in: PubMed
    Score: 0.010
  7. Olopatadine hydrochloride ophthalmic solution for the treatment of allergic conjunctivitis. Expert Opin Pharmacother. 2017 Aug; 18(11):1137-1143.
    View in: PubMed
    Score: 0.004
  8. World Allergy Organization Anaphylaxis Guidelines: 2013 update of the evidence base. Int Arch Allergy Immunol. 2013; 162(3):193-204.
    View in: PubMed
    Score: 0.003
  9. Pharmacokinetic evaluation of olopatadine for the treatment of allergic rhinitis and conjunctivitis. Expert Opin Drug Metab Toxicol. 2011 Dec; 7(12):1593-9.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.